Mylan at session lows amid new volley of EpiPen criticism

Shares of Mylan (MYL) ticked lower in afternoon trading after news of additional scrutiny surrounding the pricing of its EpiPen product, including criticism by Democratic presidential candidate Hillary Clinton and an information request from the Senate Special Committee on Aging. CLINTON CONTINUES PHARMA RHETORIC: Continuing her critical look at the pharmaceutical space, Hillary Clinton released a statement Wednesday saying EpiPen's price increases over the last several years are "outrageous," adding that the move is the "latest troubling example" of profit-seeking by drug companies. SENATE SEEKS BRIEFING FROM CEO: Senate Special Committee on Aging chair Susan Collins and top Democrat Claire McCaskill issued a letter Wednesday to Mylan CEO Heather Bresch requesting a briefing on EpiPen pricing "no later than two weeks from today." AMA COMES OUT AGAINST PRICE HIKES: The American Medical Association also took a stance against EpiPen Wednesday, saying, "Though the product is unchanged since 2009, the cost has skyrocketed by more than 400% during that period. The AMA has long urged the pharmaceutical industry to exercise reasonable restraint in drug pricing, and, with lives on the line, we urge the manufacturer to do all it can to rein in these exorbitant costs." MYLAN RESPONDS TO GROWING CRITICISM: Today's three statements against the EpiPen price increases build on another three set of statements from Senators released Monday, which prompted Mylan to comment at the time that "we are proud of the programs which we have implemented over the past several years to help support access to treatment, including our My EpiPen Savings Card, a patient assistance program... With the current changes in the healthcare insurance landscape, an increasing number of people and families have enrolled in high deductible health plans, and deductible amounts continue to rise. This current and ongoing shift has presented new challenges for consumers, and now they are bearing more of the cost." PRICE ACTION: Shares of Mylan are down 1.5% to $44.95 in afternoon trading.